Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14759594 | 1.00 | FAAH (0.50) | FAAHTRPV1EPHX2LPAR1LPAR3 | |
| SCHEMBL20017981 | 1.00 | FAAH (0.50) | FAAHTRPV1EPHX2LPAR1LPAR3 | |
| SCHEMBL12179827 | 1.00 | FAAH (0.50) | FAAHTRPV1EPHX2LPAR1LPAR3 | |
| SCHEMBL12179849 | 1.00 | FAAH (0.50) | FAAHTRPV1EPHX2LPAR1LPAR3 | |
| SCHEMBL12179809 | 1.00 | FAAH (0.50) | FAAHTRPV1EPHX2LPAR1LPAR3 | |
| SCHEMBL22814028 | 0.96 | EPHX2 (0.50) | FAAHTRPV1EPHX2LPAR1LPAR3 | |
| SCHEMBL22022981 | 0.96 | EPHX2 (0.50) | FAAHTRPV1EPHX2LPAR1LPAR3 | |
| SCHEMBL22022994 | 0.96 | EPHX2 (0.50) | FAAHTRPV1EPHX2LPAR1LPAR3 | |
| SCHEMBL20030175 | 0.96 | EPHX2 (0.50) | FAAHTRPV1EPHX2LPAR1LPAR3 | |
| SCHEMBL20030173 | 0.96 | EPHX2 (0.50) | FAAHTRPV1EPHX2LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2567951-B1 | CATIONIC LIPID | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-09-19 | — | — | EP | disclosed |
| EP-3301086-A1 | PRODUCTION OF A COMPOSITION CONTAINING A COMPLEX BETWEEN A MEMBRANE COMPOSED OF A LIPID MONOLAYER AND A NUCLEIC ACID, AND, A LIPID MEMBRANE FOR ENCAPSULATING THE COMPLEX THEREIN | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9920028-B2 | Cationic lipid | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2018-03-20 | — | — | US | disclosed |
| US-9845306-B2 | Cationic lipid | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-19 | — | — | US | disclosed |
| US-20170349532-A1 | CATIONIC LIPID | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| US-20160304487-A1 | CATIONIC LIPID | KYOWA HAKKO KIRIN CO LTD (JP) | 2016-10-20 | — | — | US | disclosed |
| US-9408914-B2 | Cationic lipid | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20150343062-A1 | CATIONIC LIPID | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-12-03 | — | — | US | disclosed |
| EP-2774912-A1 | CATIONIC LIPID | Kyowa Hakko Kirin Co., Ltd. (JP) | 2014-09-10 | — | — | EP | disclosed |
| US-20130280305-A1 | CATIONIC LIPID | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-10-24 | — | — | US | disclosed |
| US-20130129811-A1 | CATIONIC LIPID | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-05-23 | — | — | US | disclosed |
| US-20130108685-A1 | CATIONIC LIPID | KYOWA KIRIN CO., LTD. (JP) | 2013-05-02 | — | — | US | disclosed |
| EP-2567952-A1 | CATIONIC LIPID | Kyowa Hakko Kirin Co., Ltd. (JP) | 2013-03-13 | — | — | EP | disclosed |
| EP-2567951-A1 | CATIONIC LIPID | Kyowa Hakko Kirin Co., Ltd. (JP) | 2013-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304487-A1 | CATIONIC LIPID | LPAR3, ACOX3, H1-3 | FAAH 1553/4885TRPV1 2408/4885EPHX2 1730/4885 |
| US-20170349532-A1 | CATIONIC LIPID | LPAR3, ACOX3, H1-3 | FAAH 1553/4885TRPV1 2408/4885EPHX2 1730/4885 |
| US-20130108685-A1 | CATIONIC LIPID | LPAR3, ACOX3, H1-3 | FAAH 1553/4885TRPV1 2408/4885EPHX2 1730/4885 |
| US-20130280305-A1 | CATIONIC LIPID | LPAR3, ACOX3, H1-3 | FAAH 1553/4885TRPV1 2408/4885EPHX2 1730/4885 |
| US-20130129811-A1 | CATIONIC LIPID | ACOX3, LPCAT1, ACOX1 | FAAH 2044/4885TRPV1 1700/4885EPHX2 2314/4885 |
| US-20150343062-A1 | CATIONIC LIPID | ACOX3, LPAR3, ELOVL3 | FAAH 1555/4885TRPV1 2410/4885EPHX2 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.